Abstract
Despite numerous studies on multiple sclerosis (MS) and understanding many aspects of this disease, researchers still struggle to find proper biomarkers that facilitate diagnosis; prognosis and monitoring of treatment efficacy in MS. MicroRNAs (miRNAs) are considered as endogenous, comparatively stable and small non-coding RNAs involved in various biological and pathological signaling pathways. Interestingly, miRNAs have been emerged as a potential biomarker for monitoring novel therapies in MS patients. In this review, we described the miRNAs alteration in the MS patients as well as their altered expression in patients under common MS therapies.
Acknowledgements
The authors wish to apologize to the all authors whose outstanding study has not been mentioned here due to space limitations. There are no funders to report for this study.
Disclosure statement
The authors declare no potential conflicts of interest.
Author’s contributions
S.R and H.Y and wrote the manuscript. M.G designed and supervised the study.